STOCK TITAN

Draganfly Completes First Proof-of-Concept Flights in Drone Delivery Research Project for Mass General Brigham

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Draganfly Inc. (NASDAQ: DPRO) has successfully completed initial proof-of-concept flights for a drone delivery research project with Mass General Brigham (MGB) Home Hospital. The project's first phase, focused on the greater Boston area, involved route mapping and test flights within hospital infrastructure to evaluate how drone deliveries could improve access to medical supplies and laboratory samples.

The initiative aims to address healthcare logistics challenges by reducing delays caused by traffic congestion and outdated delivery methods. While these initial test flights did not contribute to care delivery, they represent a significant step toward developing more efficient healthcare delivery systems. Draganfly also showcased its medical delivery technologies at the World Medical Innovation Forum in Boston.

Draganfly Inc. (NASDAQ: DPRO) ha completato con successo i voli iniziali di prova di concetto per un progetto di ricerca sulla consegna di droni in collaborazione con Mass General Brigham (MGB) Home Hospital. La prima fase del progetto, concentrata sull'area metropolitana di Boston, ha comportato la mappatura delle rotte e voli di prova all'interno delle infrastrutture ospedaliere per valutare come le consegne con droni possano migliorare l'accesso a forniture mediche e campioni di laboratorio.

L'iniziativa mira a affrontare le sfide logistiche nel settore sanitario riducendo i ritardi causati dalla congestione del traffico e dai metodi di consegna obsoleti. Anche se questi voli di prova iniziali non hanno contribuito alla fornitura di cure, rappresentano un passo significativo verso lo sviluppo di sistemi di consegna sanitaria più efficienti. Draganfly ha inoltre presentato le proprie tecnologie di consegna medica al World Medical Innovation Forum di Boston.

Draganfly Inc. (NASDAQ: DPRO) ha completado con éxito los vuelos iniciales de prueba de concepto para un proyecto de investigación sobre la entrega de drones con Mass General Brigham (MGB) Home Hospital. La primera fase del proyecto, centrada en el área metropolitana de Boston, involucró la planificación de rutas y vuelos de prueba dentro de la infraestructura hospitalaria para evaluar cómo las entregas con drones podrían mejorar el acceso a suministros médicos y muestras de laboratorio.

La iniciativa tiene como objetivo abordar los desafíos logísticos en el sector de la salud mediante la reducción de retrasos provocados por la congestión de tráfico y métodos de entrega desactualizados. Aunque estos vuelos de prueba iniciales no contribuyeron a la entrega de atención médica, representan un paso significativo hacia el desarrollo de sistemas de entrega de salud más eficientes. Draganfly también presentó sus tecnologías de entrega médica en el World Medical Innovation Forum de Boston.

드래건플라이 Inc. (NASDAQ: DPRO)매사추세츠 일반 브리검 (MGB) 홈 병원과의 드론 배송 연구 프로젝트를 위한 초기 개념 증명 비 flights를 성공적으로 완료했습니다. 이 프로젝트의 첫 번째 단계는 보스턴 대도시 지역에 중점을 두고 병원 인프라 내에서 경로 계획 및 시험 비행을 포함하여 드론 배송이 의료 용품 및 실험실 샘플에 대한 접근성을 어떻게 향상시킬 수 있는지를 평가했습니다.

이 이니셔티브는 교통 혼잡과 구식 배송 방법으로 인한 지연을 줄여 의료 물류 문제를 해결하는 것을 목표로 합니다. 이러한 초기 시험 비행은 치료 제공에 기여하지는 않았지만, 보다 효율적인 의료 제공 시스템 개발을 향한 중요한 걸음을 나타냅니다. 드래건플라이는 또한 보스턴에서 열린 세계 의료 혁신 포럼에서 의료 배송 기술을 선보였습니다.

Draganfly Inc. (NASDAQ: DPRO) a réussi à réaliser les premiers vols de preuve de concept pour un projet de recherche sur la livraison par drone avec Mass General Brigham (MGB) Home Hospital. La première phase du projet, axée sur la région de Boston, a impliqué la cartographie des itinéraires et des vols d'essai au sein de l'infrastructure hospitalière pour évaluer comment les livraisons par drone pourraient améliorer l'accès aux fournitures médicales et aux échantillons de laboratoire.

Cette initiative vise à relever les défis logistiques du secteur de la santé en réduisant les retards causés par la congestion du trafic et des méthodes de livraison obsolètes. Bien que ces premiers vols d'essai n'aient pas contribué à la livraison des soins, ils représentent une étape significative vers le développement de systèmes de livraison de soins de santé plus efficaces. Draganfly a également présenté ses technologies de livraison médicale au World Medical Innovation Forum à Boston.

Draganfly Inc. (NASDAQ: DPRO) hat erfolgreich die ersten Konzeptnachweisflüge für ein Forschungsprojekt zur Drohnenlieferung in Zusammenarbeit mit Mass General Brigham (MGB) Home Hospital abgeschlossen. Die erste Phase des Projekts, die sich auf das Großraum Boston konzentrierte, umfasste die Routenplanung und Testflüge innerhalb der Krankenhausinfrastruktur, um zu bewerten, wie Drohnenlieferungen den Zugang zu medizinischen Lieferungen und Laborproben verbessern könnten.

Die Initiative zielt darauf ab, die Herausforderungen der Logistik im Gesundheitswesen zu bewältigen, indem Verzögerungen durch Verkehr und veraltete Liefermethoden reduziert werden. Obwohl diese ersten Testflüge nicht zur Versorgung beigetragen haben, stellen sie einen bedeutenden Schritt in Richtung der Entwicklung effizienterer Gesundheitssysteme dar. Draganfly präsentierte auch seine medizinischen Liefertechnologien auf dem World Medical Innovation Forum in Boston.

Positive
  • Successful completion of initial proof-of-concept flights with major healthcare institution Mass General Brigham
  • Strategic expansion into healthcare logistics market through medical delivery infrastructure development
  • Partnership with prestigious healthcare provider potentially opening new market opportunities
Negative
  • None.

Insights

The successful completion of proof-of-concept flights for medical drone delivery at Mass General Brigham represents a significant milestone in healthcare logistics innovation. The project's focus on the greater Boston area, known for its traffic congestion, could serve as a valuable test case for urban healthcare delivery optimization. While this initial phase only involved test flights without actual care delivery, it sets the foundation for potential widespread implementation.

The integration of drone technology in hospital infrastructure addresses critical timing issues in healthcare delivery, particularly for home hospital care where rapid access to medical supplies and laboratory samples can impact patient outcomes. However, the project is still in early stages and requires extensive regulatory approvals and safety validations before commercial implementation.

Draganfly's proprietary drone technology application in healthcare logistics demonstrates strategic market positioning in a high-value sector. The collaboration with a prestigious institution like Mass General Brigham provides valuable validation for Draganfly's technical capabilities. The project's successful initial phase, including infrastructure integration and route mapping, showcases the company's ability to adapt its technology for complex healthcare applications.

However, investors should note that this is still a proof-of-concept stage, with significant technical, regulatory and operational hurdles ahead before any commercial deployment. The project's success could position Draganfly as a pioneer in medical drone delivery infrastructure, but monetization timeline remains uncertain.

Draganfly’s medical drone delivery infrastructure offers new model for future improvement in service time for Home Hospital care

Boston, MA., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc.(NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) ("Draganfly" or the "Company"), an award-winning, industry-leading drone solutions and systems developer, today announced the successful completion of initial flights as part of a proof-of-concept, research-and-development drone delivery project for Mass General Brigham (MGB) Home Hospital.

This initial phase involved collaborating with MGB and regulators to evaluate and map potential routes as well as complete test flights that included takeoff and landing within hospital infrastructure. These test flights did not contribute to care delivery. This initiative aims to demonstrate how drone deliveries could ensure timely access to critical medical supplies or laboratory samples, thereby minimizing traditional logistical delays.

Phase One of the project focuses on the greater Boston metropolitan area to identify how Draganfly’s proprietary drone technology addresses healthcare logistics challenges by reducing delays caused by traffic congestion and outdated delivery methods.

"This is a first step toward our vision of someday delivering high-quality healthcare directly to patients' homes in a more timely and cost-effective manner,” said Dr. David Levine, MD, MPH, MA, Clinical Director of Research & Development at Mass General Brigham Healthcare at Home.

"We are thrilled to see the progress of our drone delivery services with Mass General Brigham. Draganfly’s hope is to establish a transformation in how healthcare providers manage logistics, enabling faster, more reliable delivery of essential supplies that directly benefits patients and care providers alike," commented Cameron Chell, CEO of Draganfly.

Draganfly also participated in the World Medical Innovation Forum, an annual event run by Mass General Brigham that focuses on the latest advancements in medical technology and healthcare innovations. The Forum, which ran from September 23-25 in Boston, MA, attracted healthcare professionals and leaders in medical research and development to discuss and explore new ways to improve patient care and treatment options. Draganfly displayed various technologies used in the medical delivery project during the event.

About Draganfly

Draganfly Inc. is the creator of quality, cutting-edge drone solutions, software, and AI systems that revolutionize how organizations operate and serve their stakeholders. With over 24 years of innovation, Draganfly is recognized as a leader in the public safety, agriculture, industrial inspections, security, mapping, and surveying markets. The Company’s commitment to ingenuity and first-class services drives its goal to save time, money, and lives across the globe.

For more information on Draganfly, please visit Draganfly’s website. For additional investor information, visit:

Media Contact Erika Racicot Email: media@draganfly.com

Company Contact Email: info@draganfly.com

Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking ‎‎‎‎information” as ‎‎‎‎defined under applicable securities laws. Forward-looking statements ‎‎‎‎and information can ‎‎‎‎generally be identified by the use of forward-looking terminology such as ‎‎‎‎‎“may”, “will”, “expect”, “intend”, ‎‎‎‎‎“estimate”, “anticipate”, “believe”, “continue”, “plans” or similar ‎‎‎‎terminology. Forward-looking statements ‎‎‎‎and information are based on forecasts of future ‎‎‎‎results, estimates of amounts not yet determinable and ‎‎‎‎assumptions that, while believed by ‎‎‎‎management to be reasonable, are inherently subject to significant ‎‎‎‎business, economic and ‎‎‎‎competitive uncertainties and contingencies. Forward-looking statements ‎‎‎‎include, but are not ‎‎‎‎limited to, statements with respect to the ability of drones to address healthcare logistics challenges by reducing delays caused by traffic congestion and outdated delivery methods. Forward-‎‎‎‎looking statements and information are subject to various ‎known ‎‎and unknown risks and ‎‎‎‎‎uncertainties, many of which are beyond the ability of the Company to ‎control or ‎‎predict, that ‎‎‎‎may cause ‎the Company’s actual results, performance or achievements to be ‎materially ‎‎different ‎‎‎‎from those ‎expressed or implied thereby, and are developed based on assumptions ‎about ‎‎such ‎‎‎‎risks, uncertainties ‎and other factors set out here in, including but not limited to: the potential ‎‎‎‎‎‎‎impact of epidemics, ‎pandemics or other public health crises, including the ‎COVID-19 pandemic, on the Company’s business, operations and financial ‎‎‎‎condition; the ‎‎‎successful integration of ‎technology; the inherent risks involved in the general ‎‎‎‎securities markets; ‎‎‎uncertainties relating to the ‎availability and costs of financing needed in the ‎‎‎‎future; the inherent ‎‎‎uncertainty of cost estimates; the ‎potential for unexpected costs and ‎‎‎‎expenses, currency ‎‎‎fluctuations; regulatory restrictions; and liability, ‎competition, loss of key ‎‎‎‎employees and other related risks ‎‎‎and uncertainties disclosed under the ‎heading “Risk Factors“ ‎‎‎‎in the Company’s most recent filings filed ‎‎‎with securities regulators in Canada on ‎the SEDAR ‎‎‎‎website at www.sedar.com and with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at www.sec.gov. The Company undertakes ‎‎‎no obligation to update forward-‎looking ‎‎‎‎information except as required by applicable law. Such forward-‎‎‎looking information represents ‎‎‎‎‎managements’ best judgment based on information currently available. ‎‎‎No forward-looking ‎‎‎‎statement ‎can be guaranteed and actual future results may vary materially. ‎‎‎Accordingly, readers ‎‎‎‎are advised not to ‎place undue reliance on forward-looking statements or ‎‎‎information.‎


FAQ

What is the purpose of Draganfly's drone delivery project with Mass General Brigham?

The project aims to demonstrate how drone deliveries could ensure timely access to critical medical supplies and laboratory samples, reducing traditional logistical delays in healthcare delivery.

What has Draganfly (DPRO) accomplished in Phase One of the Mass General Brigham project?

In Phase One, Draganfly completed initial test flights, route mapping, and evaluations within hospital infrastructure in the greater Boston metropolitan area.

How will Draganfly's drone delivery service benefit Mass General Brigham's Home Hospital program?

The service aims to provide faster, more reliable delivery of essential medical supplies, potentially improving service time and cost-effectiveness for home hospital care.

Where did Draganfly (DPRO) showcase its medical delivery technology in 2024?

Draganfly showcased its medical delivery technologies at the World Medical Innovation Forum in Boston, MA, from September 23-25.

Draganfly Inc. Common Shares

NASDAQ:DPRO

DPRO Rankings

DPRO Latest News

DPRO Stock Data

22.20M
5.38M
1.28%
1.82%
3.66%
Aerospace & Defense
Industrials
Link
United States of America
Saskatoon